|Bid||0.00 x 1200|
|Ask||0.00 x 1000|
|Day's Range||42.19 - 42.45|
|52 Week Range||37.43 - 45.86|
|Beta (3Y Monthly)||0.49|
|PE Ratio (TTM)||21.76|
|Forward Dividend & Yield||1.86 (4.34%)|
|1y Target Est||49.00|
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination.
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
In the past, pharmaceutical companies have attributed high prices to innovation, arguing that new and improved drugs are naturally more expensive . Looking at wholesale data for around 27,000 prescription drugs, Hernandez and her colleagues found that, between 2008 and 2016, brand-name oral prescription drugs rose 9 percent annually, while injectable drugs increased 15 percent per year.
have raised prices of insulin in the US, despite political pressure as diabetics protest and lobby lawmakers over the rising cost of the essential medicine. Sanofi increased the price of its three main insulin brands by between 4.4 per cent and 5.2 per cent last week, while Novo Nordisk increased the price of its insulin products by just under 5 per cent on Tuesday. Depending on the dose and brand, the list prices for insulin products vary between $300 and $400.
just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. The justices declined to hear Amgen's appeal seeking reinstatement of a jury verdict it won against Regeneron and Sanofi in the dispute in which Amgen accused its rivals of infringing its patents relating to its competing drug Repatha and sought to block sales of Praluent.
Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-oncology discovery programme costs for the last quarter of 2018.
Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes.
Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million. The companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently, while Regeneron retains all rights to its other immuno-oncology discovery and development programs. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the immuno-oncology discovery program costs for the last quarter of 2018, and up to $120 million in other development costs.
The U.S. Food and Drug Administration approved Sanofi's new paediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday. Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck. Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenzae type B.
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered into an exclusive global licensing agreement with Sanofi (SNY) for the development and commercialization of drinabant for the treatment of acute cannabinoid overdose (ACO). Opiant intends to develop drinabant, a cannabinoid CB-1 receptor antagonist, as an injectable for administration in an emergency department setting.
An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Vaccine revenue In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.
GlaxoSmithKline stock jumped early Wednesday after the pharmaceutical stock struck a deal with Pfizer to combine their consumer health divisions, which brought in $12.7 billion in 2017.
PARIS, Dec. 18, 2018 /PRNewswire/ -- Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018, after market close. Sanofi's ADSs are expected to begin trading as a Nasdaq-listed security at market open on January 2, 2019, and will continue to be listed under the ticker symbol "SNY." This transition will not impact the company's primary listing on Euronext (SAN.NX). "This partnership with Nasdaq is a natural transition for Sanofi as it provides greater cost-efficiencies as well as access to a broad-based portfolio of investor relations tools to enhance both market insights and our interaction with the financial community," said Jean-Baptiste Chasseloup de Chatillon, Executive Vice President, Chief Financial Officer, Sanofi.